Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival | Zendy

Mario Giovanni Chilelli | Zendy; Carlo Signorelli | Zendy; Julio Rodrigo Giròn Berrìos | Zendy; Angelo Onorato | Zendy; Fabrizio Nelli | Zendy; Agnese Fabbri | Zendy; Francesca Primi | Zendy; Eleonora Marrucci | Zendy; Antonella Virtuoso | Zendy; Marta Schirripa | Zendy; Marco Mazzotta | Zendy; Enzo Maria Ruggeri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival

Author(s) -

Mario Giovanni Chilelli,

Carlo Signorelli,

Julio Rodrigo Giròn Berrìos,

Angelo Onorato,

Fabrizio Nelli,

Agnese Fabbri,

Francesca Primi,

Eleonora Marrucci,

Antonella Virtuoso,

Marta Schirripa,

Marco Mazzotta,

Enzo Maria Ruggeri

Publication year - 2022

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10076

Subject(s) - medicine , immunotherapy , immune system , oncology , lung cancer , thyroid dysfunction , retrospective cohort study , thyroid , non small cell lung cancer (nsclc) , thyroid cancer , gastroenterology , cancer , immunology , a549 cell

There is no clear information on the proportion of patients who need therapy for immune-related thyroid dysfunction (irTD) or who need to delay, omit, or discontinue immunotherapy. Furthermore, it is not well known whether irTD correlates with better outcomes or not.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research